In a report released on March 17, Corentin Marty from TP ICAP MIDCAP maintained a Buy rating on PharmaNutra SpA (PHN – Research Report), with a price target of €74.00.
Corentin Marty has given his Buy rating due to a combination of factors that highlight PharmaNutra SpA’s strong financial performance and strategic growth initiatives. The company reported a solid EBITDA margin of 26.6% despite significant investments in new business units, particularly in the USA. This indicates efficient management and a robust business model capable of sustaining profitability while expanding.
Moreover, PharmaNutra’s return to a strong cash generation level, with a free cash flow of €16.9M and a net cash position of €5.6M, underscores its financial health. The positive outlook for the international segment and the continued growth of the SiderAL e-commerce platform in China further support the company’s growth potential. Although there are some revisions in revenue expectations, the overall strategic direction and financial stability justify the Buy recommendation.
In another report released on March 17, Stifel Nicolaus also reiterated a Buy rating on the stock with a €88.00 price target.
PHN’s price has also changed moderately for the past six months – from EUR59.200 to EUR49.750, which is a -15.96% drop .